Handelsbanken Fonder AB Sells 444,592 Shares of Abbott Laboratories $ABT

Handelsbanken Fonder AB lowered its position in Abbott Laboratories (NYSE:ABT) by 37.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 736,804 shares of the healthcare product maker’s stock after selling 444,592 shares during the period. Handelsbanken Fonder AB’s holdings in Abbott Laboratories were worth $66,858,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Nia Impact Advisors LLC raised its holdings in shares of Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after purchasing an additional 79 shares in the last quarter. Riggs Asset Managment Co. Inc. boosted its holdings in Abbott Laboratories by 9.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock worth $140,000 after purchasing an additional 88 shares in the last quarter. GHP Investment Advisors Inc. increased its position in Abbott Laboratories by 0.3% during the fourth quarter. GHP Investment Advisors Inc. now owns 29,411 shares of the healthcare product maker’s stock worth $3,685,000 after buying an additional 92 shares during the last quarter. Eley Financial Management Inc raised its holdings in Abbott Laboratories by 0.9% during the fourth quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock valued at $1,355,000 after buying an additional 92 shares in the last quarter. Finally, Copley Financial Group Inc. lifted its position in shares of Abbott Laboratories by 2.1% in the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock worth $556,000 after buying an additional 93 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 0.8%

ABT opened at $108.65 on Tuesday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a market capitalization of $188.01 billion, a P/E ratio of 35.16, a P/E/G ratio of 2.09 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm’s fifty day moving average price is $95.93 and its two-hundred day moving average price is $99.79.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the firm earned $1.26 EPS. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of analyst reports. Sanford C. Bernstein lowered their price objective on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. BTIG Research upped their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday. Daiwa Securities Group cut shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research note on Wednesday, April 22nd. Finally, Citigroup upped their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.17.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.